G Yothers

A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study.

D. Kerr, S. Shak, D. Watson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.

M Buyse, D. Sargent, M. Buyse, 2011, European journal of cancer.

Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803.

M Buyse, D J Sargent, D. Sargent, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.